Researchers at the University of Maryland have discovered a novel approach to treating venomous snakebites by studying the natural defenses found in rattlesnake blood. The study, led by Distinguished University Professor Sean B. Carroll and published in the Proceedings of the National Academy of Sciences, identifies specific toxin-blocking proteins that snakes have evolved to protect themselves from accidental self-envenomation.
Venomous snakebites remain a significant global health concern, with the World Health Organization estimating that snakes kill between 80,000 and 140,000 people annually, while hundreds of thousands of survivors suffer permanent disabilities. Current antivenom treatments, typically produced by exposing large animals to snake venom and harvesting their antibodies, have substantial limitations including high manufacturing costs, variable effectiveness, and potential serious immune reactions. These challenges have motivated scientists to explore alternative solutions.
The research team focused on a protein called FETUA-3, which was previously identified in 2022 as capable of blocking metalloproteinase toxins found in western diamondback rattlesnake venom. The new findings demonstrate that while individual FETUA proteins can counter specific venom effects—such as reducing bleeding or interfering with enzyme activity—none alone provides complete protection against lethal snakebites. However, when researchers combined multiple FETUA proteins, the protective effects increased dramatically.
Laboratory experiments showed that optimized combinations of these proteins were approximately ten times more potent than current sheep-derived rattlesnake antivenoms, completely neutralizing the lethal effects of rattlesnake venom while providing broad protection against venoms from multiple viper species. The conservation of these inhibitor proteins over millions of years of snake evolution underscores their critical importance to snake survival.
The research team is now applying the same strategy to target other major venom toxin families, with expectations that nature-based, recombinant antivenoms could be commercially viable in the near term. Researchers anticipate initial applications in veterinary medicine, potentially followed by human treatments, offering safer, less expensive, and more easily manufactured alternatives to conventional antivenoms.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI